$RLMD

Relmada Therapeutics saw a 25% surge in its stock price following the release of promising data related to its bladder cancer treatment. The positive results from the clinical trials have bolstered investor confidence and heightened interest in the company as a potential leader in the oncology space. Market analysts are now projecting significant future growth as more data is anticipated. This surge reflects broader optimism in the biotech sector, particularly for companies making advancements in cancer treatment. Investors are advised to monitor the stock for possible volatility as further news develops.